Proteon Therapeutics Inc (PRTO): George Arthur Eldridge, , CFO of Proteon Therapeutics Inc purchased 4,000 shares on Jun 6, 2016. The Insider buying transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were purchased at $5.77 per share for a total value of $23,109.80 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 5, 2016, Timothy P Noyes (President and CEO) sold 5,000 shares at $13.88 per share price.On Jul 8, 2015, Daniel Philip Gottlieb (VP Marketing & Bus Development) sold 1,965 shares at $16.86 per share price.
Shares of Proteon Therapeutics Inc (PRTO) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -3.76% at $5.88 with 24,804 shares getting traded. Post opening the session at $6.09, the shares hit an intraday low of $5.77 and an intraday high of $6.1 and the price vacillated in this range throughout the day. The company has a market cap of $97 M and the number of outstanding shares has been calculated to be 1,65,66,635 shares. The 52-week high of Proteon Therapeutics Inc is $20 and the 52-week low is $5.105.
Company has been under the radar of several Street Analysts.Proteon Therapeutics Inc is Initiated by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $20. The Rating was issued on Apr 14, 2016.Proteon Therapeutics Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 19 from a previous price target of $20 . The Rating was issued on Mar 15, 2016.
Proteon Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is primarily involved in research and development activities. The Company’s product candidate PRT-201 is a recombinant human elastase that it is developing to reduce vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of PRT-201 in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials for PRT-201 in radiocephalic AVFs.